Don’t let fibromyalgia pain drain your finances along with your energy. We help eligible patients access Savella (milnacipran) for as little as $69.95 per month through manufacturer Patient Assistance Programs
The Savella Prescription Assistance Program is a manufacturer-sponsored initiative that provides Savella at no medication cost to qualifying patients who cannot afford it. The program is available uninsured and underinsured U.S. residents who meet income and residency requirements. If approved, you receive your medication at no cost and can reapply for continued access.
Fibromyalgia is an invisible illness — the widespread pain, crushing fatigue, and cognitive fog are real and debilitating, but they don’t show up on an X-ray or blood test. Many patients have spent years being told their pain is “all in their head” before finally receiving a diagnosis. When your doctor prescribes Savella as one of only three FDA-approved medications for this condition, the financial burden compounds the physical one.
AffordMyPrescriptions ensures cost never stands between you and the relief you deserve. For a flat $69.95 per month, our Patient Advocates manage every step of your enrollment.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$500.00 | Save ~$430/mo |
| CVS Pharmacy | ~$510.00 | Save ~$440/mo |
| Walmart | ~$490.00 | Save ~$420/mo |
| Costco | ~$485.00 | Save ~$415/mo |
| Kroger | ~$475.00 | Save ~$405/mo |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
Living with fibromyalgia means fighting a daily battle against pain, fatigue, and the frustration of a condition that many people — sometimes even healthcare providers — don’t fully understand. When you finally find a medication that helps manage your symptoms well enough to reclaim some normalcy, losing access because of cost can feel like losing a hard-won victory.
Our trained Patient Advocates manage every administrative detail on your behalf, so you can focus on managing your fibromyalgia rather than navigating a complex healthcare system. They prepare your application, coordinate with your rheumatologist, pain specialist, or prescriber, submit everything to the appropriate program, and track your status through every stage.
Our pricing is simple and predictable: $69.95 per month — every month, without exception. While the medication itself is provided at no cost through the manufacturer’s program, our monthly fee covers all advocacy, application management, doctor coordination, and refill oversight. If we’re unable to secure access, you won’t be charged.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through Afford My Prescriptions is the better long-term solution:
$20 copay card excludes Medicare/Medicaid/government insurance
Fixed $69.95/month — never changes regardless of retail price
Brand-name medication supplied directly from the manufacturer
Eligibility is generally determined by annual household income levels. Most programs follow guidelines that include a limit of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Contact us so we can review your specific situation and determine if you qualify for assistance.
Savella (milnacipran) is a twice-daily prescription tablet used to manage fibromyalgia in adults. It is available in 12.5 mg, 25 mg, 50 mg, and 100 mg tablets, with treatment typically starting at a low dose and gradually increasing over the first week. Unlike most other SNRIs, Savella is approved exclusively for fibromyalgia — not for depression — and works by increasing levels of both serotonin and norepinephrine in the brain and spinal cord.
How It Works:
Fibromyalgia causes the central nervous system to amplify pain signals through a process called central sensitization. Savella addresses this by increasing levels of serotonin and norepinephrine, which helps regulate the body’s “volume control” for pain. It is unique among similar medications for its high potency in blocking norepinephrine reuptake, specifically targeting the pathways that dampen incoming pain.
Form and Use:
Savella is available in tablet strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg. The standard dosage is one tablet taken twice daily, usually with food to improve tolerance. To minimize adjustment effects, the dose is gradually increased over the first week of treatment.
Generic Availability:
Although the FDA has approved a generic version of milnacipran, it is not yet commercially available or in stock at U.S. pharmacies as of April 2026. Brand-name Savella remains the only current option, often costing between $466–$771 per month at retail. Patients can access the brand-name medication more affordably through the AffordMyPrescriptions Patient Assistance Program for $69.95 per month.
Warnings:
This medication includes a boxed warning concerning the increased risk of suicidal thoughts and behaviors in young adults. Users should never discontinue Savella abruptly due to the risk of withdrawal symptoms and should only do so under medical supervision. Common side effects may include nausea, headaches, constipation, and elevated blood pressure.
The average retail price is approximately $466–$771 per month depending on dose and quantity. With SingleCare coupons, the lowest price is approximately $482. The manufacturer offers a $20 copay savings card for commercially insured patients ($1,200 max/year). Through AffordMyPrescriptions, qualifying patients receive Savella at no medication cost — our $69.95 monthly fee covers advocacy and program management.
Yes. The Savella supplied through the Patient Assistance Program is the same FDA-approved milnacipran medication dispensed at retail pharmacies, supplied directly from the manufacturer.
The FDA has approved generic milnacipran, but it is not yet commercially available at U.S. pharmacies. Until the generic reaches the market, brand-name Savella is the only option, and the PAP provides the most affordable access.
Both are SNRIs approved for fibromyalgia. Savella has relatively greater norepinephrine activity, which may provide distinct pain reduction benefits. Generic duloxetine is dramatically more affordable at $4–$15/month — if your doctor determines duloxetine could work for you, it’s far cheaper. Savella is typically prescribed when duloxetine hasn’t provided adequate relief.
Some patients notice improvement within the first 1 to 2 weeks, but full benefit may take several weeks. Your doctor will start you on a low dose and gradually increase it over the first week. Continue taking Savella as prescribed even if you don’t notice immediate relief, and never stop abruptly without medical guidance.
Our Patient Advocates will immediately explore every alternative — including the manufacturer’s $20 copay savings card, GoodRx and SingleCare coupons, independent co-pay assistance foundations, insurance formulary exception requests, and alternative fibromyalgia medications including generic duloxetine ($4–$15/month), generic pregabalin (Lyrica generic), or other pain management approaches.
If you are struggling with the high cost of Savella, our team may be able to help you access assistance programs designed to make medications more affordable. Check your eligibility today and take the first step toward reducing your prescription costs.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.